FDA grants expedited review for Francis Medical prostate cancer treatment


The U.S. Food and Drug Administration is expediting the review process for Francis Medical’s prostate cancer therapy technology, a process that happens when a new treatment is more effective than current standards of care.

Previous HealthPartners exits office in downtown St. Paul
Next Applications for expanded Reconstruct Challenge are now open